The Influence of Genetic and Environmental Factors on the Occurrence and Development of Blood Diseases

Qiaoling Wang; Qing Yuan; Jiayu Liu; Shenglin Hu; Junwu Du; Shuzhi Zhou

Authors

Qiaoling Wang Ya'an People's Hospital, Ya'an, Sichuan, China Author
Qing Yuan Ya'an People's Hospital, Ya'an, Sichuan, China Author
Jiayu Liu Ya'an People's Hospital, Ya'an, Sichuan, China Author
Shenglin Hu Ya'an People's Hospital, Ya'an, Sichuan, China Author
Junwu Du Ya'an People's Hospital, Ya'an, Sichuan, China Author
Shuzhi Zhou Ya'an People's Hospital, Ya'an, Sichuan, China Author

Keywords:

blood diseases, gene mutation, environmental exposure

Abstract

Hematopoietic disease is due to the abnormal function of the hematopoietic system, is a disease caused by the dual role of heredity and environment. Genetic factors such as gene mutation, chromosome abnormality, immune gene mutation, as well as environmental factors such as exposure to harmful chemicals, viral infection, and living habits are all risk factors for causing blood diseases. Certain gene mutations, such as TP53, JAK2, NPM1, etc., are high-risk for the occurrence of blood diseases, and long-term exposure to harmful chemicals, EBV virus infection, etc., can also lead to the occurrence of blood diseases. This article reviews the influence of genetic and environmental factors on the occurrence and development of blood diseases, and discusses the prevention and control strategies such as early screening, targeted therapy, cell therapy and personalized rehabilitation.

References

1. M. Arora, A. Kilcoyne, J. Bolodeoku, et al., "Has the UK lost its position as a destination for world-leading clinical research? A comparative analysis of haematological cancer clinical trials performance before Brexit," BMJ Open, vol. 14, no. 12, p. e086058, 2024, doi: 10.1136/bmjopen-2024-086058.

2. Q. Huang, H. Li, and Y. Zhang, "A bibliometric and knowledge-map study on the treatment of hematological malignancies with CAR-T cells from 2012 to 2023," Hum. Vaccin. Immunother., vol. 20, no. 1, p. 2371664, 2024, doi: 10.1080/21645515.2024.2371664.

3. H. Li, Q. Huang, and Y. Zhang, "Response to 'A bibliometric and knowledge-map study on the treatment of hematological malignancies with CAR-T cells from 2012 to 2023: A correspondence'," Hum. Vaccin. Immunother., vol. 20, no. 1, p. 2386225, 2024, doi: 10.1080/21645515.2024.2386225.

4. H. Zhao, J. Xu, K. Xu, et al., "Comment on 'A bibliometric and knowledge-map study on the treatment of hematological ma-lignancies with CAR-T cells from 2012 - 2023'," Hum. Vaccin. Immunother., vol. 20, no. 1, p. 2408881, 2024, doi: 10.1080/21645515.2024.2408881.

5. M. A. Rudzite, D. Auzina, and S. Lejniece, "Factors affecting COVID-19 outcomes in patients with hematological malignancies," Exp. Oncol., vol. 46, no. 3, pp. 260–267, 2024, doi: 10.15407/exp-oncology.2024.03.260.